Table 6

Univariate analyses of clinical and tumor factors associated with EpCAM/CD133 in 39 HCC patients
Variables Epcam CD133
P value OR 95% CI P value OR 95% CI
Age (≥55/<55) 0.719 1.27 0.34-4.73 0.726 1.25 0.39-4.36
Gender (Female/male) 0.656 1.50 0.25-9.00 0.101 4.17 0.76-23.07
AFP (ng/ml) (≥20/<20) 0.066 3.75 0.92-15.34 1.000 1.00 0.29-3.48
Tumor number (≥2/1) 0.206 2.37 0.62-9.03 0.162 0.43 0.13-1.41
Tumor size,cm (≥3/<3) 0.547 0.67 0.18-2.49 0.292 1.89 0.58-10.93
TNM stage 0.206 2.37 0.62-9.25 0.068 0.30 0.08-1.10
Differentiation 0.033 5.36 1.15-25.06 0.154 2.4 0.72-7.97
(well/moderate/poor)
TACE treatment/not 0.012 6.43 1.57-27.45 0.070 3.47 0.90-13.31

AFP,α-fetoprotein; TACE, Transarterial chemoembolization.

Zeng et al.

Zeng et al. BMC Cancer 2012 12:584   doi:10.1186/1471-2407-12-584

Open Data